SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 10, 2014
TARGETED MEDICAL PHARMA, INC.
(Exact name of registrant as specified in its charter)
or other jurisdiction
2980 Beverly Glen Circle, Suite 301
Los Angeles, California
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including area code: (310) 474-9809
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 4, 2014, Targeted Medical Pharma, Inc. (the “Company”) appointed Dr. Thomas Wenkart to serve as a director on the Company’s Board of Directors. Dr. Wenkart will also serve as the Chairman of the Company’s Compensation Committee. There were no arrangements or understandings pursuant to which Dr. Wenkart was appointed as a director of the Company. On December 23, 2013, Dr. Wenkart purchased 416,667 shares of the Company’s common stock, par value $0.001 per share, from the Company for a total purchase price of $250,000.
Item 8.01 Other Events.
On March 10, 2014, the Company issued a press release announcing the appointment of Dr. Wenkart as a director of the Company. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
The following exhibits are filed with this Current Report on Form 8-K:
|99.1||Press Release dated March 10, 2014|
|99.2||Dr. Tom Wenkart - Bio|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 11, 2014
|TARGETED MEDICAL PHARMA, INC.|
|By:||/s/ William B. Horne|
|Name:||William B. Horne|
|Title:||Chief Financial Officer|
|Targeted Medical Pharma|
|Marcus Charuvastra | firstname.lastname@example.org|
|ProActive Capital Group|
|Jeff Ramson | email@example.com|
Healthcare Executive Dr. Thomas Wenkart Joins Targeted Medical Pharma’s Board of Directors
Los Angeles, March 5, 2014 –Targeted Medical Pharma, Inc. (OTCQB:TRGM) today announced that Dr. Thomas Wenkart, Chief Executive and Chairman at Macquarie Health Corporation, has joined the company’s board of directors.
A nationally respected expert in healthcare, medical and hospital administration in Australia, Dr. Wenkart established Macquarie Health Corporation in Sydney, Australia in 1976. His organization owns and operates eleven private hospitals in Australia, and is one of the nation’s leading providers of healthcare services.
Dr. Wenkart is a graduate of the Sydney University School of Medicine. In 1976, he established the Health Care Research Institute and the Wenkart Foundation which supports the Arts and Health Sciences with the credo of “community benefits in the shortest possible time.” In 2007 the Wenkart Foundation established the Wenkart Chair of the Endothelium at Sydney University and the Centenary Institute. Dr. Wenkart has a unique understanding and interest in, medical computing, electronic health records, biomedical technology, and videodermoscopy systems. In 2003, he acquired Derma Medical Systems in Austria.
“We are very pleased to have Dr. Wenkart join our company. He brings a great deal of healthcare and business experience to our board,” said Dr. William Shell, Chief Executive Officer and Chief Science Officer at Targeted Medical Pharma. “His expertise in operations and management systems will help the continued growth and execution of strategic initiatives of our company in the United States and abroad.”
About Targeted Medical Pharma, Inc.
Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness. The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™. The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.
Forward Looking Statement
This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.
# # # #
Dr Thomas R Wenkart
Dr. Thomas Wenkart attended Sydney University and graduated as a medico in 1968. He went to Royal Newcastle Hospital and entered General Practice and the world of medical computing in 1970. Dr. Wenkart acquired his first private hospital interest in 1978 and has since expanded Macquarie Hospital Services in Sydney and an interest in the Bega Valley Private Hospital day centre complex.
Macquarie Hospital Services includes five (5) private hospitals which cater for surgery, rehabilitation and medical services. Each hospital is undergoing significant development and expansion of their facilities.
In 1976, Dr. Wenkart established the Health Care Research Institute and the Wenkart Foundation which supports the Arts and Health Sciences with the credo of “community benefits in the shortest possible time.” In 2007 the Wenkart Foundation established the Wenkart Chair of the Endothelium at Sydney University and the Centenary Institute.
Dr. Wenkart’s medico-political interests included many years of involvement in the AMA system as an office-bearer and also likewise in the private hospital sector in the 1970s and 1980s. He also completed his MPH at Sydney University in the 1990s.
Over the years support and active participation in the Arts has been diverse and includes Musica Viva, Opera Foundation Australia, Sydney Eisteddfod, Opera and Arts Foundation and more recently the Sydney Conservatorium of Music. Support and promotion of Australian talent overseas and specifically Europe, is a current endeavor.
Dr. Wenkart’s most recent endeavor involves electronic medical records. He firmly believes that the future for Electronic Medical Records are Personal Health Records controlled by individuals as a life-long health record.